Baekje Shenzhou is a China life science biotechnology company headquartered in Beijing, which is committed to exploring and developing new anti-tumor drugs effective for common cancers in China and Asia-Pacific region. This company has a wide range of business and many employees, so its economic strength is very strong and it also provides many jobs for the society.
The Development of Baekje in China
WIND data shows that in the first quarter, three or six pharmaceutical listed companies settled in the top 500 market capitalization. There are 6 billion enterprises. Compared with the four enterprises at the end of 20 17, biopharmaceuticals from Unacon and China were increased.
Among them, Baekje Shenzhou and Tiger Pharmaceutical ranked higher. Baekje Shenzhou has been committed to investing in innovative drugs. 20 17 performance report shows that the company's R&D expenditure is USD 269.02 million, and the average growth rate of R&D investment in recent three years exceeds 150%. Coupled with the policy express, locally developed innovative drugs can start clinical trials simultaneously in China and around the world, making Baekje China develop more rapidly.
Finally, among the 42 listed pharmaceutical companies, Baekje Shenzhou is the fastest growing company with a growth rate of 3 18%. In addition, China Biopharmaceutical, Xinhecheng and Hutchison China Medical Technology are also the fastest growing companies. Baekje Shenzhou is a new biomedical company, focusing on new molecular targeted drugs and tumor immune drugs for cancer treatment.